CA-ADTRAN
22.3.2024 14:01:28 CET | Business Wire | Press release
Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC). Central to the showcase is Adtran’s FSP 3000 open line system (OLS), which delivers 400Gbit/s OpenZR+ transceiver interoperability across a 1,000km link. The OLS features advanced automation and optimization for maximum performance and user-friendly operation. Involving 47 member companies, the demo marks a major milestone in open networking and highlights the commitment of the OIF community to driving the future of high-performance, efficient and scalable network solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322753779/en/
Adtran’s FSP 3000 OLS is playing a central role in the OIF’s biggest interoperability demo to date. (Photo: Business Wire)
“Interoperability continues to be at the heart of our vision for the future of optical networking. This year, by showcasing our FSP 3000 OLS’s capacity for 400Gbit/s OpenZR+ transceiver interoperability over regional distances, we’re pushing the boundaries of end-to-end network performance,” said Stephan Neidlinger, VP of global business development at Adtran. “Together with our fellow industry innovators at the OIF, we’re spotlighting what can be achieved when we unite behind intelligent, open architectures. This shared dedication to supporting multi-vendor environments will ensure superior network performance and new levels of flexibility for our customers.”
The demo uses Adtran’s FSP 3000 OLS to interconnect 400Gbit/s OpenZR+ pluggable transceivers from different suppliers over a bidirectional link that extends up to 1,000km. This comprises eight spans and utilizes Corning’s SMF-28 ULL and Contour fibers. The setup uses compact amplification modules integrating EDFA and Raman amplification, OSC, monitor ports and auto-span equalization. This enables an OLS configuration with a high degree of integration, performance, automation and ease of use. It also features terminal nodes with flexible multi-degree ROADMs for power equalization and scalability. The configuration provides an open hardware platform with programmable interfaces that pave the way for interoperability across various data rates, modulation formats and upgrades to 800Gbit/s transport.
“This demo is a testament to the power of strategic collaboration and technological integration, epitomizing the core principles our FSP 3000 OLS was built upon: openness, scalability and cutting-edge performance. Through concerted efforts with our OIF partners, from renowned component manufacturers to key industry players, we’re crafting solutions that will provide the adaptability and optical prowess our customers need for the networking challenges they face,” commented Ryan Schmidt, GM of optical transport at Adtran. “By focusing on customized solutions and embracing an ecosystem-wide approach, Adtran is not only tackling current network complexities but also setting the stage for future advancements, ensuring that our customers will always stay ahead of the game.”
About the OIF demo
OIF to Showcase Interoperability at OFC 2024 with Nearly 50 Member Companies Collaborating to Address Unprecedented Demand for Next-Generation Network Solutions.
OIF’s interoperability demonstration at OFC 2024 will feature 47 member companies showcasing breakthrough solutions in speed, power and density to meet the growing demands of next-generation data center networking, AI/ML and disaggregation applications. See the solutions in 800ZR, 400ZR and OpenZR+ optics, Energy Efficient Interfaces (EEI) & Co-Packaging, Common Electrical I/O (CEI) channels and Common Management Interface Specification (CMIS) implementations that are playing a pivotal role in shaping the industry for the next decade. Experience these live and interactive demonstrations at booth #1323. For more information, visit: www.oiforum.com/meetings-events/oif-ofc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322753779/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom